Literature DB >> 30987780

New analogs of SYA013 as sigma-2 ligands with anticancer activity.

Gladys Asong1, Xue Y Zhu1, Barbara Bricker1, Terrick Andey1, Felix Amissah1, Nazarius Lamango1, Seth Y Ablordeppey1.   

Abstract

Our previous study has revealed 4-(4-(4-chlorophenyl)-1,4-diazepan-1-yl)-1-(4-fluorophenyl)butan-1-one·2HCl (SYA013) 1 as a sigma ligand with moderate selectivity for the sigma-2 receptor. Given the overexpression of sigma receptors in solid tumors and reports of sigma ligands with anticancer activities, we selected 1 for evaluation in several solid tumor cell lines. In addition, we have synthesized new analogs of 1 and now report that several of them bind preferentially at the sigma-2 receptor and have shown inhibition of several cancer cell lines including MDA-MB-231, MDA-MB-486, A549, PC-3, MIA PaCa-2 and Panc-1 cells. In particular, compounds 1 and 12 have demonstrated sub-micromolar activity against the Panc-1 cell line. It has also been observed that several of these compounds demonstrate selective toxicity toward cancer cells, when compared to normal cells. Published by Elsevier Ltd.

Entities:  

Keywords:  Anticancer activity; Homopiperazine; Indanone; Oxime; Sigma receptors; Sigma-2 receptor

Year:  2019        PMID: 30987780      PMCID: PMC6536312          DOI: 10.1016/j.bmc.2019.04.012

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  46 in total

1.  A proposal for the classification of sigma binding sites.

Authors:  R Quirion; W D Bowen; Y Itzhak; J L Junien; J M Musacchio; R B Rothman; T P Su; S W Tam; D P Taylor
Journal:  Trends Pharmacol Sci       Date:  1992-03       Impact factor: 14.819

Review 2.  Sigma receptors and cancer: possible involvement of ion channels.

Authors:  Ebru Aydar; Christopher P Palmer; Mustafa B A Djamgoz
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

3.  Sigma ligands inhibit the growth of small cell lung cancer cells.

Authors:  T W Moody; J Leyton; C John
Journal:  Life Sci       Date:  2000-04-07       Impact factor: 5.037

4.  Overexpression of sigma receptors in nonneural human tumors.

Authors:  W T Bem; G E Thomas; J Y Mamone; S M Homan; B K Levy; F E Johnson; C J Coscia
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

5.  KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.

Authors:  S Soga; L M Neckers; T W Schulte; Y Shiotsu; K Akasaka; H Narumi; T Agatsuma; Y Ikuina; C Murakata; T Tamaoki; S Akinaga
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

6.  Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.

Authors:  Katrina R Bauer; Monica Brown; Rosemary D Cress; Carol A Parise; Vincent Caggiano
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

7.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

8.  The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines.

Authors:  Ebru Aydar; Pinar Onganer; Rebecca Perrett; Mustafa B Djamgoz; Christopher P Palmer
Journal:  Cancer Lett       Date:  2006-01-04       Impact factor: 8.679

Review 9.  Sigma receptors. Putative links between nervous, endocrine and immune systems.

Authors:  T P Su
Journal:  Eur J Biochem       Date:  1991-09-15

10.  Sigma-2 receptors as a biomarker of proliferation in solid tumours.

Authors:  K T Wheeler; L M Wang; C A Wallen; S R Childers; J M Cline; P C Keng; R H Mach
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

View more
  5 in total

1.  Selectivity profile comparison for certain γ-butyrolactone and oxazolidinone-based ligands on a sigma 2 receptor over sigma 1: a molecular docking approach.

Authors:  Richie R Bhandare; Dilep Kumar Sigalapalli; Afzal B Shaik; Daniel J Canney; Benjamin E Blass
Journal:  RSC Adv       Date:  2022-07-11       Impact factor: 4.036

2.  A study of the structure-affinity relationship in SYA16263; is a D2 receptor interaction essential for inhibition of apormorphine-induced climbing behavior in mice?

Authors:  Edem K Onyameh; Barbara A Bricker; Suresh V K Eyunni; Chandrashekhar Voshavar; Uma M Gonela; Edward Ofori; Andrea Jenkins; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2020-12-14       Impact factor: 3.641

3.  A Mechanistic Investigation on the Anticancer Properties of SYA013, a Homopiperazine Analogue of Haloperidol with Activity against Triple Negative Breast Cancer Cells.

Authors:  Gladys M Asong; Felix Amissah; Chandrashekhar Voshavar; Augustine T Nkembo; Elizabeth Ntantie; Nazarius S Lamango; Seth Y Ablordeppey
Journal:  ACS Omega       Date:  2020-12-16

4.  Synthesis of σ Receptor Ligands with a Spirocyclic System Connected with a Tetrahydroisoquinoline Moiety via Different Linkers.

Authors:  Melanie Bergkemper; Dirk Schepmann; Bernhard Wünsch
Journal:  ChemMedChem       Date:  2021-02-02       Impact factor: 3.466

5.  Novel Sigma-2 receptor ligand A011 overcomes MDR in adriamycin-resistant human breast cancer cells by modulating ABCB1 and ABCG2 transporter function.

Authors:  Zhanwei Zeng; Shiyi Liao; Huan Zhou; Hongyu Liu; Jiantao Lin; Yunsheng Huang; Chenhui Zhou; Daohua Xu
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.